The case iPierian profiles a start-up biotechnology company uses the recent development of induced pluripotent stem cells (iPS cells) of the adult stem cells that have been reprogrammed to a “pluripotent” state in which they can differentiate into about 200 different cell types in the body . The science in this area is in the nascent stages but the pace of change is rapid, as new discoveries are made, because the company and develop applications for the technology. iPierian has established itself as a … Read more »

The case iPierian profiles a start-up biotechnology company uses the recent development of induced pluripotent stem cells (iPS cells) of the adult stem cells that have been reprogrammed to a “pluripotent” state in which they can differentiate into about 200 different cell types in the body . The science in this area is in the nascent stages but the pace of change is rapid, as new discoveries are made, because the company and develop applications for the technology. iPierian has established itself as the early leader in the space by creating a consistent manner to create large amounts of high-quality iPSCs and then to differentiate these cells into motor neurons. The company has between three main tools, drug development of therapeutics in which they control the company and continue to develop their technology. Must also decide iPierian this decision related to the role of large pharmaceutical players in the industry with which they find either partner or potentially compete against in the race for successful applications for iPSC technology.
«Hide

from
Robert Chess,
Sara Rosenthal
Source: Stanford University
26 pages.
Release Date: 4 February 2011. Prod #: E393-PDF-ENG
iPierian HBR case solution

[related_post themes="flat"]